Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effect of dose on safety, tolerability, and immunogenicity of ACAM1000 smallpox vaccine in adults without previous smallpox vaccination. A phase 2, randomized, double-blind, dose-response study.

Next Previous
Trial Profile

The effect of dose on safety, tolerability, and immunogenicity of ACAM1000 smallpox vaccine in adults without previous smallpox vaccination. A phase 2, randomized, double-blind, dose-response study.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACAM 2000 (Primary)
  • Indications Smallpox
  • Focus Adverse reactions
  • Sponsors Sanofi Pasteur

Most Recent Events

  • 14 Jan 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov, last updated 14 Jan 2009.
  • 30 Sep 2008 Actual patients number added 274 as reported by ClinicalTrials.gov.
  • 30 Sep 2008 Planned end date (1 Sep 2003) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top